Does Semaglutide Affect Pregnancy — and When Should You Stop?

The biggest misconception: that stopping once you find out is good enough

A widely held assumption is that semaglutide is only a concern once a pregnancy test turns positive. In practice, UK guidance goes further than that. The MHRA advises that women who could become pregnant should use effective contraception throughout treatment and for a period afterwards before trying to conceive. The reasoning is straightforward: by the time a home test reads positive, an embryo has already been developing for weeks, and that early window is precisely when developmental risks are highest.

This isn't a theoretical concern invented by regulators to be cautious. Animal reproductive toxicity studies, referenced in the semaglutide SmPC published on the electronic Medicines Compendium, showed effects on foetal development at doses relevant to human exposure. Human data is limited, because pregnant women are not enrolled in clinical weight-loss trials, so absence of evidence is not evidence of absence of harm.

The practical implication: stopping semaglutide should happen before conception, with timing agreed with your prescriber, not after a positive test. That is a meaningfully different message from 'stop if it happens'.

What happens to weight and blood sugar when semaglutide is stopped in pregnancy

A concern our prescribers hear regularly is what happens to appetite and weight when treatment pauses for a pregnancy. It is worth being straightforward about this. Semaglutide significantly suppresses appetite; when it is withdrawn, hunger signals typically return over the following weeks. Weight regain is common without it, and this can feel alarming when someone has worked hard to reduce their weight.

For the majority of people, this is a manageable transition with the right support. Your GP or an NHS weight management team can advise on nutrition and activity during pregnancy, where the goals are different from weight-loss treatment. If you have type 2 diabetes, management of blood sugar in pregnancy will also need adjustment, and if you are curious about when semaglutide was approved for use in diabetes, that background helps explain why stopping requires an alternative plan agreed with your diabetes team. You can read more about the broader effects of semaglutide on the body's systems on our page covering how semaglutide affects the heart and cardiovascular system.

The NHS weight-management injections guidance, published by NHS England, is explicit that these medicines are not appropriate during pregnancy and recommends discussing a plan with your clinical team before stopping.

Contraception considerations specific to semaglutide

One practical detail that catches people off guard: semaglutide slows gastric emptying, which can in theory reduce how reliably oral contraceptives are absorbed. UK guidance notes that this effect is most pronounced in the early weeks of treatment. The NHS page on weight-management injections recommends discussing your contraception method with a prescriber when starting a GLP-1 medicine, particularly if you rely on oral contraceptives taken at a fixed time, say, first thing in the morning before the kettle goes on.

Tirzepatide (Mounjaro) carries an explicit recommendation to add a barrier method for four weeks at the start and after each dose increase; the equivalent evidence for semaglutide is less definitive, but the precaution is still worth raising. More detail on how these drugs interact with pregnancy planning is covered in our overview of how Wegovy can affect pregnancy and on the dedicated Wegovy and pregnancy page.

If you are unsure whether your current contraception is affected, your GP or a sexual health clinic can advise without you needing to change your weight-management plan.

Who to speak to, and when

If you are on semaglutide and planning a pregnancy, the conversation to have is with your prescriber, ideally before conception, not once it has occurred. They can advise on an appropriate wash-out period, what to expect when the medicine stops, and how to manage your weight and any related conditions through the pregnancy. If you became pregnant unexpectedly and are still taking semaglutide, stop the medicine and contact your GP or midwife today. Do not wait for a scheduled review.

For anyone who is not pregnant and not planning to be, semaglutide for weight management remains a well-studied, MHRA-licensed option. Our Wegovy treatment overview covers how the medicine works and what the trial evidence shows, including the STEP 1 study published in the New England Journal of Medicine, which reported around 15% average weight reduction over 68 weeks. Our clinical team (you can read more about our approach on the clinical team page) reviews every consultation personally.

If you have concerns about semaglutide's effects beyond pregnancy, our page on semaglutide and liver health addresses another area patients often ask about. For a broader view of licensed weight-loss options, our treatment overview sets out what is available in the UK. Suspected side effects during treatment can be reported directly at the MHRA's Yellow Card scheme. The NHS England weight-management injections guidance is the fullest official resource on pregnancy, contraception and GLP-1 medicines in one place.